Avalo Therapeutics (NASDAQ:AVTX) Research Coverage Started at Guggenheim

Guggenheim assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report report published on Monday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $50.00 price target on the stock.

Several other equities research analysts have also issued reports on AVTX. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Avalo Therapeutics in a research note on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.88.

Avalo Therapeutics Price Performance

Shares of Avalo Therapeutics stock opened at $14.37 on Monday. The firm has a market cap of $265.99 million, a price-to-earnings ratio of -2.68 and a beta of 0.88. Avalo Therapeutics has a 52-week low of $3.39 and a 52-week high of $20.72. The stock has a 50-day simple moving average of $17.22 and a 200-day simple moving average of $14.07.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($2.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). As a group, equities research analysts predict that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

A number of institutional investors have recently made changes to their positions in the business. BIT Capital GmbH bought a new stake in Avalo Therapeutics during the 3rd quarter valued at approximately $25,000. PFS Partners LLC lifted its holdings in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after buying an additional 1,000 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Avalo Therapeutics during the second quarter worth approximately $55,000. Dimensional Fund Advisors LP bought a new stake in shares of Avalo Therapeutics in the third quarter valued at approximately $143,000. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Avalo Therapeutics in the second quarter worth $56,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.